(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Most Read from BloombergBiden Set to Impose Tariffs on China EVs, Strategic SectorsAckman Scolded Over DEI Views at Closed-Door Milken SessionApple Apologizes for iPad Pro Ad, Scraps Plan to Air It on TVMarjorie Taylor Greene Finally Got What She Deserved: Defeat‘Seriously Underwater’ Home Mortgages Tick Up Across the US
Bloomberg